Replies to post #436497 on Anavex Life Sciences Corp (AVXL)

[LakeshoreLeo1953]

Not that Anavex SHOULD have incurred many "investigational" expenses,
but you don't really think there is $150M still in the Bank?

Burn Rate and lack of a "raise" would seem to discount that probability.

[WilliamMunny]

Not only that, Steady, but if either the company or the CEO bought stock, the market would know for sure that no major data release, Rett or AD, was imminent (or that the Rett data had even been received by the company). If positive news was released not too long thereafter and the stock rose appreciably, lawsuits would be initiated on behalf of the aggrieved shareholders who sold to the company or an officer.

[Doc328]

I agree a PR stating we will have THE expected PR by end of year (when it should have been out already) will be laughed at. 10k shares at $5 is pocket change and not worthy of a PR (Bas and LTB buy this many shares every few days) - 200,000 shares may have an impact.

The only PR that matters should already be written with 6 blanks. RSBQ delta A273, RSBQ delta placebo, p and CGI-I delta A273, CGI-I delta placebo, p. Could also add c.i. After the June 6 PR, Any attempt to replace these numbers or equivalents with other data will appropriately be bashed.

In communication with the FDA, the Company received the Agency’s input on the study endpoints, which were utilized in this clinical study. The Rett Syndrome Behavior Questionnaire (RBSQ) total score and Clinical Global Impression Improvement Scale (CGI-I) score are co-primary endpoints in the statistical analysis plan with specified linear mixed-effects models for repeated measures (MMRM) as the primary analysis methods.

[tredenwater2]

Nicely stated and all three open the company up for future lawsuits.

Instead its best for Dr Kun Jin to just get the results lined up on how the Fda wants to see them (like the company has stated) and puts the best surrogate biomarkers in the best light possible against precedence where applicable.